Täger M, Kröning H, Thiel U, Ansorge S
Institute of Experimental Internal Medicine, Otto-von-Guericke University of Magdeburg, Germany.
Exp Hematol. 1997 Jul;25(7):601-7.
The proteindisulfide isomerase (PDI), a multifunctional cytoplasmic enzyme with additional chaperone activity, has been shown recently, using monoclonal antibodies, to be located on the membrane of mature human B lymphocytes and B cell chronic lymphocytic leukemia (B-CLL) cells. Here, evidence is presented that this antigen exhibits catalytic activity as measured by the reductive degradation of insulin (release of A chain molecules) on intact B cells in patients suffering from B-CLL, as well as on JVM 13 cells (B-CLL cell line). More than 98% of these cells exhibited PDI activity which could be inhibited by bacitracin and also by monoclonal and polyclonal antibodies to PDI. Interestingly, surface PDI expression was strongly correlated in our study with protein-bound membrane SH groups. These surface protein thiols were specifically determined by using low concentrations of the chloromethyl-derivative based fluorescent probe 5-(and6)-(((4-chloromethyl)-benzoyl)amino)-tetramethyl-rhodamine (CMTMR) at low temperature in the presence of sodium azide in flow cytometry. The highest PDI and SH expression was found on B lymphocytes, particularly B-CLL cells. The mean fluorescence intensity (MFI) of CMTMR-positive B cells in the B-CLL line was up to 10-fold higher than that of controls, indicating a strong elevation of cell membrane-located protein thiols on malignant B cells. The link between PDI and SH expression on cell surfaces points to a functional interaction between the two. Treatment with bacitracin resulted in a strong inhibition of PDI and a dramatic increase in surface protein thiol expression of B-CLL cells. Similar effects could be observed by cell treatment with anti-PDI antibodies, indicating that this enzyme system plays a crucial role in the regulation of protein-bound SH groups. Interestingly, artificially induced protein thiol expression led to significantly higher cellular resistance to the cytostatic drugs chlorambucil, vinblastin, and cisplatin in vitro as measured by cell growth. These data suggest for the first time a regulatory effect of PDI on the surface protein thiol status of B cells. The increased expression of PDI may play a crucial role in SH-mediated protection and drug resistance in malignant B lymphocytes.
蛋白二硫键异构酶(PDI)是一种具有额外伴侣活性的多功能细胞质酶,最近通过单克隆抗体显示其位于成熟人B淋巴细胞和B细胞慢性淋巴细胞白血病(B-CLL)细胞的膜上。本文提供的证据表明,在患有B-CLL的患者的完整B细胞以及JVM 13细胞(B-CLL细胞系)上,通过胰岛素的还原降解(A链分子的释放)来衡量,该抗原具有催化活性。超过98%的这些细胞表现出PDI活性,杆菌肽以及抗PDI的单克隆和多克隆抗体均可抑制该活性。有趣的是,在我们的研究中,表面PDI表达与蛋白质结合的膜SH基团密切相关。这些表面蛋白硫醇是通过在低温下,在叠氮化钠存在的情况下,使用低浓度的基于氯甲基衍生物的荧光探针5-(和6)-(((4-氯甲基)-苯甲酰基)氨基)-四甲基罗丹明(CMTMR)在流式细胞术中特异性测定的。在B淋巴细胞,尤其是B-CLL细胞上发现了最高的PDI和SH表达。B-CLL细胞系中CMTMR阳性B细胞的平均荧光强度(MFI)比对照高多达10倍,表明恶性B细胞上细胞膜定位的蛋白硫醇强烈升高。细胞表面PDI和SH表达之间的联系表明两者之间存在功能相互作用。用杆菌肽处理导致PDI强烈抑制,B-CLL细胞表面蛋白硫醇表达显著增加。用抗PDI抗体处理细胞也可观察到类似效果,表明该酶系统在蛋白质结合的SH基团调节中起关键作用。有趣的是,通过细胞生长测量,人工诱导的蛋白硫醇表达导致细胞在体外对细胞毒性药物苯丁酸氮芥、长春碱和顺铂具有显著更高的抗性。这些数据首次表明PDI对B细胞表面蛋白硫醇状态具有调节作用。PDI表达的增加可能在恶性B淋巴细胞中SH介导的保护和耐药性中起关键作用。